SCHEMBL3429462

SCHEMBL3429462

c1ccc(SCc2nc3ccccc3[nH]2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 1.00
NPC1 O15118 7/20 1.00
RAB9A P51151 7/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
ALDH1A1 P00352 3/20 0.77
HPGD P15428 3/20 0.77
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
POLB P06746 2/20 0.77
LMNA P02545 5/20 0.63
HTT P42858 2/20 0.60
HSD17B10 Q99714 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MAPT P10636 1/20 0.60
KDM4E B2RXH2 1/20 0.58
TSHR P16473 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3065316 0.82 SMN1; SMN2 (0.69) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL3079520 0.82 SMN1; SMN2 (0.83) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL6485274 0.80 NPC1 (0.73) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL11130494 0.79 NPC1 (0.65) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL23657691 0.78 NPC1 (0.65) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL600508 0.78 NPC1 (1.00) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL9667165 0.76 RAB9A (0.68) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL10769877 0.76 NPC1 (0.60) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL10769872 0.76 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL7801985 0.76 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
EP-2254572-B1 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRM (US) 2013-10-16 EP claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2025-03-27 US disclosed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-11963968-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-04-23 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 SMN1; SMN2 3919/4885NPC1 1607/4885RAB9A 1434/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 SMN1; SMN2 4645/4885NPC1 1630/4885RAB9A 2455/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 SMN1; SMN2 4085/4885NPC1 1011/4885RAB9A 4314/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 SMN1; SMN2 4643/4885NPC1 1656/4885RAB9A 3020/4885
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS HES1, NOTCH1, NOTCH4 SMN1; SMN2 4643/4885NPC1 1656/4885RAB9A 3020/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 SMN1; SMN2 4190/4885NPC1 966/4885RAB9A 4168/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP SMN1; SMN2 2179/4885NPC1 1018/4885RAB9A 3293/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 SMN1; SMN2 3919/4885NPC1 1607/4885RAB9A 1434/4885
US-11963968-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 SMN1; SMN2 3919/4885NPC1 1607/4885RAB9A 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.